Inhibition of yap for breaking tumor immune tolerance
AssigneeThe Johns Hopkins University
InventorsFan PAN, Duojia PAN, Drew M. PARDOLL, Joseph BARBI, Benjamin PARK
Life of this patent
Estimating the term…
Abstract
Yes-associated protein (Yap), a downstream co-activator of the Hippo pathway, is highly expressed in the Treg cell subset, and is critical to maintain its suppressive activity. Originally discovered in Drosophila melanogaster, the Hippo signaling pathway is a major regulator of cellular growth and proliferation in mammals. Loss of Yap expression in Treg cells can lead to superior anti-tumor immune responses, and thus, Yap is an important immunotherapeutic target for cancer.
Claims21
A method of treating cancer in a subject, comprising:
- administering to the subject an inhibitor of YAP and an immunotherapeutic agent.
11-12. (canceled)
A therapeutic composition comprising:
- an inhibitor of YAP and an immunotherapeutic agent.
18-22. (canceled)
A kit for treating cancers in a subject, comprising:
- an inhibitor of YAP and an immunotherapeutic agent.
26-34. (canceled)
Dependencies are inferred from the claim text.